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Abstract
Background: The emergence and spread of Carbapenem-resistant Escherichia coli (CREC) is becoming a serious
problem in Chinese hospitals, however, the data on this is scarce. Therefore, we investigate the risk factors for
healthcare-associated CREC infection and study the incidence, antibiotic resistance and medical costs of CREC
infections in our hospital.
Methods: We conducted a retrospective, matched case–control–control, parallel study in a tertiary teaching
hospital. Patients admitted between January 2012 and December 2015 were included in this study. For patients
with healthcare-associated CREC infection, two matched subject groups were created; one group with healthcare-
associated CSEC infection and the other group without infection.
Results: Multivariate conditional logistic regression analysis demonstrated that prior hospital stay (<6 months) (OR:
3.96; 95%CI:1.26–12.42), tracheostomy (OR:2.24; 95%CI: 1.14–4.38), central venous catheter insertion (OR: 8.15; 95%CI:
2.31–28.72), carbapenem exposure (OR: 12.02; 95%CI: 1.52–95.4), urinary system disease (OR: 16.69; 95%CI: 3.01–89.
76), low hemoglobin (OR: 2.83; 95%CI: 1.46–5.50), and high blood glucose are associated (OR: 7.01; 95%CI: 1.89–26.
02) with CREC infection. Total costs (p = 0.00), medical examination costs (p = 0.00), medical test costs (p = 0.00),
total drug costs (p = 0.00) and ant-infective drug costs (p = 0.00) for the CREC group were significantly higher than
those for the no infection group. Medical examination costs (p = 0.03), total drug costs (p = 0.03), and anti-infective
drug costs (p = 0.01) for the CREC group were significantly higher than for the CSEC group. Mortality in CREC group
was significantly higher than the CSEC group (p = 0.01) and no infection group (p = 0.01).
Conclusion: Many factors were discovered for acquisition of healthcare-associated CREC infection. CREC isolates
were resistant to most antibiotics, and had some association with high financial burden and increased mortality.
Keywords: Healthcare-associated infection, Risk factors, CREC, CSEC
* Correspondence: lichunhui@csu.edu.cn; xywuanhua@csu.edu.cn
Infection Control Centre, Xiangya Hospital of Central South University,
Changsha, China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Meng et al. BMC Infectious Diseases  (2017) 17:82 
DOI 10.1186/s12879-016-2176-9
Background
Carbapenems have long served as reliable and potent
agents against Gram-negative bacilli [1]. Carbapenems
are most consistently active against members of the
Enterobacteriaceae family [2], however, few treatment
options exist for carbapenem-resistant Enterobacteria-
ceae (CRE) infection, which can result in high mortality
[3]. In recent years, carbapenem-resistant Escherichia
coli (CREC), as one class of CRE, has become a major
threat in hospitals worldwide [4–7]. Carbapenem resist-
ance in E.coli is an emerging problem that is mainly
caused by plasmid-encoded carbapenemases [8–13]. As
a result of the emergence of carbapenemases [14], anti-
microbial resistance is increasing in most hospitals, and
has become a global healthcare problem. CREC strains
should be closely monitored because of their potential
trend to spread in both hospital and community settings
[15].
There are several previous studies on the risk factors
for CRE infection [16, 17], but few published studies
have specifically evaluated the risk factors for CREC ac-
quisition, especially in China. Therefore, we performed a
retrospective study to evaluate the risk factors for
healthcare-associated infection (HAI) caused by CREC
among in-patients in a teaching hospital in central south
China, thus, we could do better in decreasing the inci-
dence of CREC infection.
The case–control–control study design of this study,
which utilizes two separate case–control analyses, has
become a standard method for the specific identification
of risk factors that are uniquely connected to infection
by antimicrobial-resistant pathogens [18, 19]. We stud-
ied the risk factors for CREC infection through the
case–control–control design. In addition, CREC is often
resistant to multiple antibiotics; therefore, we investi-
gated the antibiotic resistance and economic burden of
CREC infections.
Methods
Study design and setting
We conducted a retrospective, parallel, case–control–con-
trol study to identify the incidence, risk factors, antibiotic
resistance, and medical costs associated with the acquisi-
tion of healthcare-associated CREC infection among
hospitalized patients treated at Xiangya Hospital, a 3500-
bed general hospital in Changsha, Hunan Province,
Central South China. The CREC infection group was
compared with a no infection group to assess the risk fac-
tors for acquisition of CREC infection; meanwhile, the
CREC group was compared with the CSEC infection
group to evaluate reasons for antibiotic resistance.
Subjects with CREC or CSEC isolated from multiple
sites, or on multiple dates, were counted only once, and
the data from the first infection was included in the
study. Healthcare-acquired CREC or CSEC infection was
defined as isolation 48 hours after admission to the
hospital. Healthcare-associated infection (HAI) was de-
fined according to the CDC/NHSN surveillance criteria
in patients with samples from any specimen source site
positive for CR-EC or CS-EC; meanwhile, the patients
with CR-EC or CS-EC colonization and community-
associated infection (CAI) were ruled out.
Study population
Patients from whom CREC were isolated from clinical
cultures from any source between January 1, 2012 and
December 31, 2015 were included in this study. For each
CREC patient, we randomly selected two controls from
hospitalized patients who were admitted within the same
period with CSEC isolated, and the two groups were
matched for age and sex. Additionally, we selected two
controls from the in-patients admitted within the study
period with no bacterial infection, and the two groups
were matched for age and sex.
Microbiological identification and susceptibility testing
An automated broth microdilution method (Vitek 2; bio-
Mérieux, Marcy-l′Étoile, France) was used to perform
identification and susceptibility testing. Carbapenem
resistance was determined using the disk diffusion
method. All isolates with resistance, or intermediate
susceptibility to carbapenem were defined as resistant
isolates. Clinical and Laboratory Standards Institute
document M100-S22 (January 2012) was used for inter-
pretation of the antimicrobial susceptibility testing and
ESBL testing, and CREC was defined as E.coli resistant
to at least one of the carbapenems (imipenem, merope-
nem, or ertapenem).
Using current EUCAST breakpoints, imipenem MICs
of CR-KP isolates ranged from 2 to >32 μg/ml (break-
point for resistance and intermediate susceptibility
MIC ≥ 2 μg/ml); meropenem MICs from 4 to > 32 μg/ml
(breakpoint for resistance and intermediate susceptibility
MIC ≥ 4 μg/ml); all the isolates had ertapenem MICs in
the resistant range (breakpoint for resistance and inter-
mediate susceptibility MIC ≥ 1 μg/ml).
Data collection
Data were obtained from patients’ medical records, and
relative data were recorded on structured abstraction
forms. Variables analyzed as possible predictors included
demographics (age, sex, marital status, and ward class);
clinical departments where strains were isolated; and the
history of admission before the infection (within 6 months
prior to E.coli infection); length of hospital, intensive care
unit (ICU) stay before E.coli infection; specimen source
site (blood, bile, etc.); invasive procedures (urinary cath-
eter insertion, mechanical ventilation, etc.) within 1 month
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prior to E.coli infection; surgical procedures within
1 month prior to E.coli infection; administration of drugs
(glucocorticoids and immunosuppressive agents), radio-
therapy and chemotherapy within 1 month prior to E.coli
infection; specific co-morbidities included many system
diseases (respiratory, central nervous, etc.); exposure
(greater than, or equal to, one day) to antimicrobials
(cephalosporins, carbapenems, etc.) within 3 months prior
to CREC identification.
We also noted any related laboratory results when
healthcare-aquired isolation of E.coli was recorded in the
inspection system, and recorded the drug sensitivity test
results obtained from the microbiology laboratory and
the economic costs associated with these patients as
noted in the financial system. The economic costs in-
cluded total costs, medical examination costs, medical
test costs, total drug costs and anti-infective drug costs.
Statistical analysis
Continuous variables were presented as mean ± SD, and
we used t-tests for comparisons. As the results of the
age and average costs of the data for the three groups
showed non-normal distribution, they were compared
with the median, and the data for two groups were com-
pared using the Wilcoxon rank-sum test. We presented
categorical variables as numbers and percentages, and
compared percentages using the chi-square test or
Fisher’s exact test.
We performed univariate analyses for each of the vari-
ables using conditional logistic regression to compare
the cases and controls in terms of risk factor analysis.
The association between independent variables is shown
as the odds ratio with 95% confidence intervals, and var-
iables for which the P value was less than 0.05 in the
univariate analysis were included in a conditional logistic
regression model for multivariate analysis. Multivariate
logistic regression models were used to compare each
case group and control group. A forward elimination
process was used, and adjusted odds ratios and 95%
confidence intervals were calculated.
A two-tailed P value of less than 0.05 was considered to
show statistical significance, and statistical analyses were
performed using SPSS 17.0 (SPSS, Inc, Chicago, IL, USA).
Results
Incidence of CREC infection
During the 4-year study period, CREC was isolated from
49 patients who met the criteria for healthcare-
associated infection (HAI), including fourteen patients
in 2012 (0.13/10,000 patient days), seventeen patients in
2013 (0.15/10,000 patient days), eight patients in 2014
(0.06/10,000 patient days), and ten patients in 2015
(0.10/10,000 patient days). The incidence of CREC infec-
tion over the 4-year study presented in Fig. 1.
Specimen source site and specimen source ward
A total of 49 patients were included in the case group.
CREC was most frequently recovered from respiratory
secretions (28.6%), followed by urine (24.5%), surgical
wounds (20.4%), blood (12.2%), ascitic fluid (12.2%), and
bile (2.0%) (Fig. 2). When a positive culture result was
obtained, patients infected with CREC were most fre-
quently staying in surgical wards (46.9%), followed by
medical wards (20.4%), pediatric wards (16.3%), ICU
wards (12.2%), and the transplant center (4%) (Fig. 3).
Resistance rate to antibiotics
The antibiotic susceptibility patterns of the isolates from
the case and control patients are shown in Table 1. All
Fig. 1 Title: The incidence of carbapenem-resistant E.coli (CREC). Legend: The incidence of carbapenem-resistant E.coli (CREC) in 2012, 2013, 2014,
and 2015 are presented in the figure; we can observe the change of the incidence in the four years from the figure
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CREC strains were resistant to ampicillin, ampicillin- sul-
bactam, cefazolin, ceftriaxone, and cefepime, followed by
aztreonam, ceftazidime, ciprofloxacin, levofloxacin, piper-
acillin/tazobactam, trimethoprim and sulfamethoxazole,
cefotetan, cefoperazone/sulbactam, tobramycin, and gen-
tamicin; drug resistance rate to nitrofurantoin and amika-
cin was relatively low.
Univariate and multivariateanalyses regarding the risk
factors of the CREC and CSEC groups
Results of the univariate and multivariate analyses from the
comparison of the CREC and CSEC groups regarding the
risk factors for healthcare-acquired CREC are shown in
Table 2. The univariate conditional logistic regression ana-
lysis demonstrated that prior hospital stay (<6 months), urin-
ary catheter insertion, tracheostomy, central venous catheter
insertion, gastric tube insertion, urinary system disease, ceph-
alosporins exposure, carbapenems exposure, antifungal
agents exposure, glycopeptides and oxazolidinones exposure,
low hemoglobin, low blood albumin, and high blood glucose
were all risk factors for healthcare-acquired CREC infection.
The multivariate conditional logistic regression analysis dem-
onstrated that prior hospital stay (<6 months), incision of
trachea, central venous catheter insertion, urinary system dis-
ease, low hemoglobin, and high blood glucose were all risk
factors for healthcare-acquired CREC infection.
Univariate and multivariate analyses regarding the risk
factors in the CREC and no infection groups
The univariate and multivariate analyses results of the
CREC and no infection groups are presented in Table 3.
The univariate analysis results showed that prior hospital
stay, ICU stay, operation history, urinary catheter inser-
tion, mechanical ventilation, tracheostomy, central ven-
ous catheter insertion, bronchofiberscope use, gastric
tube insertion, wound drainage tube use, urinary system
disease, surgical trauma, cephalosporins exposure, carba-
penem exposure, antifungal agents exposure, glycopep-
tides and oxazolidinones exposure, high white blood cell
count, low hemoglobin, low blood albumin, and high
blood glucose were all risk factors for CREC infection.
Multivariate conditional logistic regression analysis dem-
onstrated that, urinary catheter insertion, central venous
catheter insertion and carbapenem exposure were all
risk factors associated with the acquisition of CREC.
Medical costs and mortality of the three groups
Comparison of the CREC and CSEC groups, and the
CREC and no infection groups, in terms of economic
costs are shown in Table 4. Mortality in the CREC group
Fig. 2 Title: The infection sites of carbapenem-resistant E.coli (CREC). Legend: The proportion of carbapenem-resistant E.coli (CREC) strains recov-
ered from the sites are presented in the figure, we can observe the regularity of the pathogens distributed
Fig. 3 Title: The infection wards of carbapenem-resistant E.coli
(CREC). Legend: The proportion of carbapenem-resistant E.coli (CREC)
strains collected in which ward are presented in this figure, we can
observe the regularity of the pathogens distributed
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was significantly higher than that in the other two
groups. In addition, medical costs of CREC group (in-
cluding total costs, medical examination costs, medical
test costs and total drug costs and anti-infective drug
costs) were statistically significantly higher than those
for the no infection group. The medical examination
costs, and total drug costs and anti-infective drug costs
for the CREC group were also statistically significantly
higher than those for the CSEC group.
Discussion
To our knowledge, few studies have evaluated the risk
factors for the acquisition of CREC infection. There-
fore, the aim of our matched case–control–control
study was to assess the potential risk factors [20] for
the acquisition of CREC in clinical specimens from
hospitalized patients and to investigate the incidence,
medical costs, and antibiotic resistance of the strains
from these infections.
During our study period, the incidence of CREC infec-
tion was lower than 1/10,000 patient days; it was likely
related to the presence of active antimicrobial steward-
ship teams in the hospital. Although the incidence of
CREC is low in CRE, carbapenem resistance in Escheri-
chia coli is also emerging worldwide; the reasons for the
spread of CREC are likely limited infection control and
antimicrobial control measures [21].
The CREC strains were resistant to at least three kind of
antibiotics, the antibiotic resistance of the CREC group
was more severe than that of the CSEC group. Compared
with the strains from the CSEC patients, most of those
from the CREC patients were resistant to cephalosporins,
penicillin, aztreonam, ciprofloxacin, and levofloxacin, but
the strains remained relatively susceptible to amikacin and
nitrofurantoin. We could not have chosen a better way to
treat CREC infections considering the above results and
according to individual clinical conditions.
The results of our study show that the CREC group
was associated with more expenses than the other
two groups, particularly in terms of the medical
examination costs, total drug costs, and anti-infective
drug costs; thus, it appears that antibiotic resistance
associated with a higher financial burden. The result
is consistent with the study of Bartsch et al. [22]. In
our study, although the mortality of the CREC group
was significantly higher than that of the CSEC and no
infection groups, mortality was not associated with
carbapenem resistance [23].
In our study, the univariate analyses of the two case–con-
trol groups found many common risk factors, including
prior hospital stay, invasive procedures such as urinary
catheter insertion [24], incision of trachea, central venous
catheter insertion, and gastric tube insertion, urinary system
disease, and antibiotic exposure (cephalosporins, carbapen-
ems, antifungal agents, glycopeptides and oxazolidinones).
In addition, our study identified unique risk factors, for
example, related laboratory results including low
hemoglobin, low blood albumin, and high blood glucose.
Multivariate analysis demonstrated a number of risk factors,
including prior hospital stay (<6 months), tracheostomy,
Table 1 The antibiotic-resistanceof the two groups {carbapenem-resistant E.coli (CREC) and carbapenem-susceptible E.coli (CSEC)}
Case (n = 49) Control (n = 98) p
Ampicillin 47/47 (100%) 90/96 (94%) 0.08
Piperacillin/tazobactam 38/48 (79%) 10/96 (10%) 0.00
Ampicillin/sulbactam 40/40 (100%) 75/88 (85%) 0.01
Cefoperazone/sulbactam 29/45 (64%) 13/96 (14%) 0.00
Cefazolin 42/42 (100%) 75/92 (82%) 0.00
Ceftazidime 37/39 (95%) 48/87 (55%) 0.00
Ceftriaxone 47/47 (100%) 75/97 (77%) 0.00
Cefepime 49/49 (100%) 50/96 (52%) 0.00
Cefotetan 22/31 (71%) 2/85 (2%) 0.00
Aztreonam 47/49 (96%) 62/97 (54%) 0.00
Tobramycin 26/45 (58%) 51/94 (54%) 0.69
Amikacin 3/48 (6%) 8/98 (8%) 0.68
Gentamicin 26/48 (54%) 49/98 (50%) 0.64
Ciprofloxacin 41/46 (89%) 64/96 (67%) 0.00
Levofloxacin 41/49 (84%) 60/96 (63%) 0.01
Trimethoprim + sulfamethoxaz ole 36/49 (73%) 58/96 (60%) 0.05
Nitrofurantoin 18/44 (41%) 20/98 (20%) 0.01
NOTE. Categorical variables are no/total no (%), case is carbapenem-resistant E.coli (CREC), control is carbapenem-susceptible E.coli (CSEC)
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urinary catheter insertion, central venous catheter insertion,
carbapenem exposure, urinary system disease, low
hemoglobin, and high blood glucose.
The identification of prior hospital stay as risk factor is
not unexpected [25]. The environment plays an import-
ant role in the spread of antimicrobial resistance, which
Table 2 Univariate and multivariate analyses regarding the risk factors of the carbapenem-resistant E.coli (CREC) and carbapenem-
susceptible E.coli (CSEC) groups
Variable Study group Univariate Multivariable
Case (n = 49) Control (n = 98) OR 95% CI P OR 95%CI P
Demographic characteristics
Sex, male (%) 20 (41%) 40 (41%) 0.57
Age {year, median (range)} 51 (0–82) 53 (0–91) 0.69
Related to hospitalization
Prior hospital stay (<6 months) 8 (77%) 57 (58%) 2.48 1.10-5.56 0.03 3.96 1.26-12.42 0.02
ICU stay (<6 months) 18 (36%) 22 (22%) 1.48 0.98-2.24 0.06
Operation history 26 (53%) 28 (29%) 2.53 1.28-5.01 0.01
Urinary catheter insertion 32 (65%) 59 (60%) 1.55 1.04-2.32 0.03
Mechanical ventilation 16 (32%) 18 (18%) 1.80 0.97-3.35 0.06
Tracheostomy 12 (24%) 10 (10%) 1.64 1.09-2.45 0.02 2.24 1.14-4.38 0.02
Bronchofibroscope use 7 (14%) 0 (0%) 72.96 0.53-9980.04 0.09
Central venous catheter insertion 15 (30%) 7 (7%) 4.48 1.72-11.67 0.00 8.15 2.31-28.72 0.00
Gastric tube insertion 28 (57%) 37 (37%) 1.53 1.09-2.16 0.01
Wound drainage tube use 18 (36%) 27 (27%) 1.46 0.93-2.29 0.09
Underlying disorder
Central nervous diseases 17 (34%) 35 (35%) 0.96 0.47-1.96 0.52
Respiratory diseases 7 (14%) 18 (18%) 0.74 0.28-1.92 0.35
Circulatory diseases 11 (22%) 24 (24%) 0.89 0.39-2.01 0.48
Endocrine diseases 7 (14%) 11 (11%) 1.32 0.48-3.64 0.39
Hematological diseases 3 (6%) 7 (7%) 0.85 0.21-3.43 0.56
Digestive system diseases 9 (18%) 23 (23%) 0.73 0.31-1.74 0.31
Urinary system diseases 11 (36%) 8 (27%) 3.61 1.23-10.61 0.02 16.69 3.01-89.76 0.00
Autoimmune diseases 3 (6%) 5 (5%) 1.21 0.28-5.30 0.54
Burn 10 (20%) 10 (10%) 2.26 0.87-5.86 0.08
Antimicrobials agents exposure
Cephalosporins a 36 (73%) 52 (53%) 2.45 1.16-5.18 0.01
Carbapenemsb 19 (38%) 19 (19%) 1.91 1.19-3.04 0.01
Antifungal agentsc 17 (35%) 9 (9%) 1.63 1.15-2.32 0.01
Anti-anaerobic agentsd 2 (4%) 3 (3%) 1.34 0.22-8.34 0.54
Glycopeptidese and Oxazolidinones 13 (26%) 10 (10%) 1.73 1.08-2.78 0.02
Relative laboratory results
Hemoglobin 104 ± 26 114 ± 26 1.71 1.13-2.59 0.01 2.83 1.46-5.50 0.00
Serum creatinine 116 ± 151 115 ± 25 2.85 0.85-9.60 0.09
Blood albumin 32 ± 7 36 ± 7 1.65 1.05-2.57 0.03
Blood glucose 9 ± 7 6 ± 3 2.59 1.16-5.77 0.02 7.01 1.89-26.02 0.00
NOTE. Categorical variables are no/total no (%), and continuous variables are mean ± SD.CI:confidence interval, OR:odds ratio
a Cephalosporins include First, second, third and fourth generation cephalosporins
bCarbapenems include imipenem, meropenem, and ertapenem
cAntifungal agents include metronidazole and tinidazole
dAnti-anaerobic agents include fluconazole, itraconazole, voriconazole and caspofungin
eGlycopeptides include vancomycin, teicoplanin, and norvancomycin
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is a limitless reservoir of antimicrobial resistance genes
[26]. Patients who fulfill the variables of prior hospital
stay and long total hospitalization time may have had
more opportunities to be exposed to additional antibi-
otics and to other patients carrying antibiotic-resistant
organisms [27]. Our result is in agreement with those
Table 3 Univariate and multivariate analyses regarding the risk factors of the carbapenem-resistant E.coli (CREC) and no infection
groups
Variable Study group Univariate Multivariable
Case (n = 49) Control (n = 98) OR 95% CI P OR 95%CI P
Demographic characteristics
Sex, male (%) 20 (41%) 37 (38%) 0.43
Age {year, median (range)} 51 (0–82) 47 (0–82) 0.34
Related to hospitalization
Prior hospital stay (<6 months) 38 (78%) 59 (60%) 2.36 1.05-5.30 0.04
ICU stay (<6 months) 18 (37%) 10 (10%) 3.05 1.60-5.82 0.00
Operation history 26 (53%) 28 (29%) 2.53 1.28-5.01 0.01
Urinary catheter insertion 32 (65%) 19 (19%) 5.34 2.58-11.06 0.00 7.14 2.37-21.49 0.00
Mechanical ventilation 16 (33%) 18 (18%) 12.45 2.92-53.05 0.00
Tracheostomy 12 (24%) 1 (1%) 7.45 1.33-41.65 0.02
Central venous catheter insertion 15 (31%) 1 (1%) 7.17 2.01-25.60 0.00 8.85 1.04-75.51 0.04
Bronchofibroscope use 7 (14%) 2 (2%) 6.74 1.52-29.83 0.01
Gastric tube insertion 28 (57%) 4 (4%) 19.25 2.77-133.69 0.00
Wound drainage tube use 18 (37%) 27 (28%) 3.04 1.60-5.78 0.00
Underlying disorder
Central nervous diseases 17 (34%) 23 (23%) 1.73 0.82-3.67 0.11
Respiratory diseases 7 (14%) 13 (13%) 1.09 0.41-2.63 0.53
Circulatory diseases 11 (22%) 21 (21%) 1.06 0.46-2.43 0.52
Endocrine diseases 7 (14%) 8 ( 8%) 1.88 0.64-5.51 0.19
Hematological diseases 3 (6%) 10 (10%) 0.57 0.15-2.19 0.31
Digestive system diseases 9 (18%) 16 (16%) 1.15 0.47-2.84 0.46
Urinary system diseases 9 (18%) 8 ( 28%) 5.06 1.37-18.76 0.02 16.79 0.72-389.5 0.07
Autoimmune diseases 3 (6%) 4 (4%) 1.53 0.33-7.13 0.01
Burn 10 (20%) 18.54 18.54 2.36-145.58 0.01
Antimicrobials agents exposure
Cephalosporins a 36 (73%) 28 (29%) 6.92 3.20-14.97 0.00
Carbapenemsb 19 (38%) 4 ( 4%) 7.41 2.46-22.36 0.00 12.02 1.52-95.4 0.01
Antifungal agentsc 17 (35%) 2 (2%) 4.72 1.65-13.52 0.00
Anti-anaerobic agentsd 2 (4%) 3 (3%) 1.35 0.22-8.34 0.54
Glycopeptidese and Oxazolidinones 13 (27%) 0 (0%) 4.69 1.53-4.31 0.01
Relative laboratory results
White blood cellcount 11 ± 7 7 ± 4 1.95 1.11-3.43 0.00
Hemoglobin 104 ± 26 122 ± 23 2.25 1.41-3.57 0.00
Blood albumin 32 ± 7 40 ± 5 4.03 2.15-7.58 0.00
Blood glucose 9 ± 7 5.5 ± 1.8 5.29 2.09-13.41 0.00
NOTE.Categorical variables are no/total no (%), and continuous variables are mean ± SD.CI:confidence interval, OR:odds ratio
aCephalosporins include First, second, third and fourth generation cephalosporins
bCarbapenems include imipenem, meropenem, and ertapenem
cAntifungal agents include metronidazole and tinidazole
dAnti-anaerobic agents include fluconazole, itraconazole, voriconazole and caspofungin
eGlycopeptides include vancomycin, teicoplanin, and norvancomycin
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of a previous study on antibiotic-resistant organisms,
which also found these variables to be risk factors
[28]. The results suggest that we need to strengthen
the management of antibiotics for long-term inpa-
tients and frequently hospitalized patients.
From these two comparisons, it is not surprising to
find that invasive procedures, including urinary catheter
insertion [24], incision of trachea, and central venous
catheter insertion [29] are risk factors for the acquisition
of CREC infection. This emphasizes the importance of
safety practice in patient care, especially the manage-
ment of devices. For example, the aseptic technique in
catheter use is important as a strategy for the prevention
of CREC infections.
There is a close association between healthcare-
associated infection and antibiotic use [30–33], espe-
cially carbapenem exposure. Thus, in order to more
accurately characterize the antibiotic exposure in our
study, we assessed the treatment with antibiotics in
the 3 months before infection for the case patients
and control patients, in this timeframe for data col-
lection is longer than that of other studies [4]. Our
findings are in line with those of a recent study that
showed the benefit of short-duration, high-dose anti-
biotic courses as a method to limit unnecessary anti-
biotic exposure, thus, reduce the risk of antibiotic
resistance [34]. According to the suggestion, treat-
ment with high doses and controlled durations is rec-
ommended to limit the risk of infections.
It is interesting that the related laboratory results includ-
ing low hemoglobin and high blood glucose are risk factors
for CREC infection, which is different from other studies.
The low hemoglobin and high blood glucose are suscepti-
bility risk factors for infection; therefore, special attention
should be paid to patients that meet these criteria. We can
closely monitor the infection index of these patients while
reducing the exposure to risk factors for infection.
One limitation of our study is that we could not assess
the patient-to-patient infection spread, we did not col-
lect isolates for gene molecular epidemiologic analysis,
thus, we could not assess if there were any outbreaks
during the study period. The second is the small study
sample size. Moreover, the financial burden is associated
with total cost of patients after isolation of CREC or
CSEC, of which the direct cost of CREC or CSEC infec-
tion was not considered.
Conclusion
Our results suggest that healthcare-acquired CREC in-
fection may be related to prior hospital stay, tracheos-
tomy, central venous catheter insertion, carbapenem
exposure, and urinary system disease. Further, anemia
and high blood glucose are important risk factors for the
acquisition of CREC infection. Hospital infection control
and the implementation of antimicrobial stewardship
practices across the continuum of healthcare settings
will hopefully help to curb the emergence and spread of
CREC infections.
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